These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32296941)

  • 1. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
    Ibraheem M; Goldstein LB
    Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
    Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cut stroke in half: Polypill for primary prevention in stroke.
    Brainin M; Feigin V; Martins S; Matz K; Roy J; Sandercock P; Teuschl Y; Tuomilehto J; Wiseman A
    Int J Stroke; 2018 Aug; 13(6):633-647. PubMed ID: 29461155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
    Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
    BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.
    Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B
    Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
    Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient preferences for a polypill for the prevention of cardiovascular diseases.
    Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
    Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
    Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
    Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of polypill use for the prevention of cardiovascular disease and strokes.
    Chrysant SG; Chrysant GS
    Am J Cardiol; 2014 Aug; 114(4):641-5. PubMed ID: 24996555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.